ArticleClinical rheumatology2026
Nonlinear relationship between erythrocyte distribution width and albumin ratio and prevalence of gout in adult hypertensive patients.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThe purpose of this study was to investigate the relationship between the new inflammatory marker erythrocyte distribution width and albumin ratio (RAR) and the development of gout.
methodsData were analyzed for gout in 10,239 adult hypertensive patients ≥ 18 years of age from the 2007-2018 NHANES survey. All patients had complete data information. Multi-model one-way and multi-factor logistic regression was used to analyze the correlation between RAR and gout, RCS curves were used to find the cut-off point, and subgroup analyses were used to assess the stability of the correlation in different groups as well as interactions. Sensitivity analyses further confirmed the stability of this correlation.
resultsData from 10,239 adult hypertensive patients were used in the study. For analysis, RAR was divided into four quartiles. The mean age of the included population was 59.3 ± 14.9 years. Among them, 896 cases had gout. Multifactorial logistic regression analysis showed that the fourth quartile was significantly associated with gout compared to the first quartile (used as reference) in all three models (model 1: OR = 2.17, 95% CI (1.76,2.66), P < 0.001; model 2: 2.12, 95% CI (1.70,2.64), P < 0.001; model 3: 1.59, 95% CI (1.26,1.99), P < 0.001). RCS curve analysis showed a significant positive nonlinear association between RAR and gout (P for nonlinear < 0.001) and an optimal cut-off value of 3.17. Subgroup analysis showed an interaction between RAR and age, smoking, alcohol consumption, and diabetes, with a significant positive association between RAR and gout in the group aged ≥ 50 years, while no such relationship was observed in those aged < 50 years. The positive association was stable in the remaining subgroups analyzed. Sensitivity analyses including all populations further confirmed this positive association.
conclusionThere was a significant positive correlation between RAR and gout. This provides new insights into the diagnosis and treatment of gout. Further prospective cohort studies on its relationship with the prognosis of gout patients are worthwhile. Key Points • This study reveals a nonlinear association between the red blood cell distribution width-to-albumin ratio (RAR) and the prevalence of gout in hypertensive patients. • The optimal cutoff value of RAR was identified, providing a novel indicator for clinical risk stratification. • A dose-response relationship was investigated using restricted cubic spline analysis. • The findings suggest that RAR may serve as a potential biomarker for gout prediction.
Indexed as
Identifiers
41733783What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.